Searchable abstracts of presentations at key conferences in endocrinology

ea0016p709 | Thyroid | ECE2008

Cinacalcet reduces serum calcium in intractable primary hyperparathyroidism (PHPT)

Marcocci Claudio , Fernandez-Cruz Laureano , Sunfa Cheng , Ren Lulu , Peacock Munro

Patients with persistent PHPT after parathyroidectomy (PTX) or contraindications for PTX often require chronic treatment for hypercalcemia, representing an unmet medical need. In an open-label, single-arm study in the US and EU, 17 patients underwent a variable length titration phase (maximum 16 weeks) with a maintenance phase (MP) of up to 3 years. Patients were eligible if they had (1) persistent PHPT following PTX or were considered contraindicated for PTX, and (2) serum ca...

ea0016p750 | Thyroid | ECE2008

Impact of Cinacalcet treatment on health related quality of life (HRQOL) in patients with primary hyperparathyroidism (PHPT) who have failed or in whom parathyroidectomy (PTX) is contraindicated

Chanson Philippe , Shoback Dolores , Lu John , Cheng Sunfa , Ren Lulu , Bilezikian John

Hypercalcemic complications of PHPT include renal, cardiovascular, gastrointestinal, neuromuscular and neuropsychiatric issues, all potentially impacting negatively on HRQOL. As control of the hypercalcemia associated with PHPT might improve HRQOL, the SF-36 and a 6-item scale on cognitive functioning (CF) were included in a phase 2, single-arm study evaluating the ability of cinacalcet to control serum calcium levels in 17 patients with intractable PHPT. Mean±S.E....